Replies to post #112041 on Cytodyn Inc (CYDY)

[Jaylimab]

Ok, so one last question Borel...

Based on the information that you have provided...do you believe that we might have to alter the primary endpoint at the interim analysis if it is deemed the CD12 trial go the full 390?

How do you see this playing out?